Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10434463" target="_blank" >RIV/00216208:11150/21:10434463 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/21:43922609 RIV/00179906:_____/21:10434463 RIV/00064173:_____/21:N0000246

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=919sY0hojB" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=919sY0hojB</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14712/18059694.2021.32" target="_blank" >10.14712/18059694.2021.32</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Popis výsledku v původním jazyce

INTRODUCTION: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. CASE REPORT: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. CONCLUSION: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.

Název v anglickém jazyce

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Popis výsledku anglicky

INTRODUCTION: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. CASE REPORT: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. CONCLUSION: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Acta Medica (Hradec Králové)

ISSN

1211-4286

e-ISSN

—

Svazek periodika

64

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

187-192

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85121960803